Kuala Lumpur – CCM Duopharma Biotech Berhad (CCMD) has entered into a collaboration with Natco Pharma Ltd of India to commercialise a range of Hepatitis C products in Malaysia to improve access and affordability for patients who currently have to fork out large sums of money for treatment in the country.
Kuala Lumpur – Once considered rare, autism is now on the rise and approximately 67 million worldwide live with autism. According to the Malaysian Department of Social Welfare, there are close to 13,000 individuals in Malaysia who are registered as autistic in 2014. Meanwhile, the Malaysian Ministry of Health reported that autism cases in the country are on the rise every year, emphasising the importance of early treatment to improve a child’s development.
Kuala Lumpur – Many champions among us often go unnoticed because their gifts and talents come in different forms that we fail to recognise. Children with autism are the unsung heroes, who are more often misunderstood than celebrated.
New Delhi, India – Malaysia’s largest generic pharmaceutical manufacturer, CCM Duopharma Biotech Berhad (CCMD), a subsidiary of Chemical Company of Malaysia Berhad (CCM) has entered into a strategic alliance with India’s Natco Pharma Limited (Natco) and Biocon Limited (Biocon) to offer affordable cancer and insulin therapies in Malaysia.
Kuala Lumpur – CCM Duopharma Biotech Berhad (CCMD), Malaysia’s largest pharmaceutical manufacturer registered a 16 per cent increase in revenue to RM312.94 million for the financialyear ended 31 December 2016 (FY 2016) from RM269.79 million in the previous year.
Kuala Lumpur – CCM Pharmaceuticals Sdn Bhd (CCMP), a subsidiary of CCM Duopharma Biotech Berhad (CCMD), and Biocon Sdn Bhd (a subsidiary of Biocon Ltd) have been awarded a Letter of Award (LOA) by the Ministry of Health (MOH) to supply Human Insulin to all government hospitals and clinics valued at RM300 million for three years until December 1, 2019.